Edition:
United States

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

29.99USD
8 Dec 2017
Change (% chg)

$0.13 (+0.44%)
Prev Close
$29.86
Open
$30.15
Day's High
$30.15
Day's Low
$29.44
Volume
8,939
Avg. Vol
38,352
52-wk High
$30.72
52-wk Low
$16.98

Chart for

About

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocyt... (more)

Overall

Beta: --
Market Cap(Mil.): $769.32
Shares Outstanding(Mil.): 25.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

Nov 27 2017

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

Nov 09 2017

BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA

* Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist

Sep 22 2017

BRIEF-Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32

* Dova Pharmaceuticals reports second quarter 2017 operating and financial results

Aug 10 2017

BRIEF-Perceptive Advisors reports 6.8 pct passive stake in Dova Pharma

* Perceptive Advisors Llc reports a 6.8 pct passive stake in Dova Pharmaceuticals Inc as of July 5 - SEC filing Source text: (http://bit.ly/2uQUtT6)

Aug 01 2017

BRIEF-Dova Pharma sees IPO to be priced between $15 and $17/shr

* Dova Pharmaceuticals Inc sees IPO of upto 4.06 million shares of common stock to be priced between $15 and $17 per share - SEC filing

Jun 19 2017

Earnings vs. Estimates